Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CEO Daniel O'Day sold 15,000 shares of the stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $169.74, for a total value of $2,546,100.00. Following the transaction, the chief executive officer owned 551,683 shares of the company's stock, valued at approximately $93,642,672.42. This trade represents a 2.65% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Daniel Patrick O'day also recently made the following trade(s):
- On Friday, October 30th, Daniel O'Day sold 15,881 shares of Gilead Sciences stock. The shares were sold at an average price of $175.25, for a total value of $2,783,145.25.
- On Thursday, October 1st, Daniel O'Day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $147.90, for a total value of $2,218,500.00.
- On Tuesday, September 1st, Daniel O'Day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $148.64, for a total value of $2,229,600.00.
Gilead Sciences Stock Down 0.2%
GILD stock opened at $170.33 on Tuesday. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The stock has a market capitalization of $211.20 billion, a P/E ratio of -53.90 and a beta of 0.31. The business has a 50-day moving average of $151.36 and a 200-day moving average of $140.03. Gilead Sciences, Inc. has a fifty-two week low of $116.88 and a fifty-two week high of $175.65.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The business had revenue of $8.30 billion during the quarter, compared to the consensus estimate of $7.81 billion. During the same period last year, the company earned $2.47 earnings per share. Gilead Sciences's quarterly revenue was up 6.8% on a year-over-year basis. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post -1.03 earnings per share for the current fiscal year.
Gilead Sciences Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Shareholders of record on Tuesday, December 15th will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a yield of 1.9%. Gilead Sciences's dividend payout ratio is -103.80%.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the stock. PFS Partners LLC increased its holdings in Gilead Sciences by 101.1% during the third quarter. PFS Partners LLC now owns 191 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 96 shares during the last quarter. Persistent Asset Partners Ltd bought a new stake in Gilead Sciences during the second quarter worth $25,000. Laurel Wealth Advisors LLC acquired a new stake in Gilead Sciences in the third quarter valued at $29,000. Kimelman & Baird LLC acquired a new stake in Gilead Sciences in the second quarter valued at $25,000. Finally, Toth Financial Advisory Corp lifted its stake in Gilead Sciences by 85.5% in the third quarter. Toth Financial Advisory Corp now owns 217 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 100 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
GILD has been the topic of a number of recent research reports. Morgan Stanley lifted their price objective on shares of Gilead Sciences from $163.00 to $183.00 and gave the company an "overweight" rating in a report on Friday. BMO Capital Markets restated an "outperform" rating and set a $184.00 target price on shares of Gilead Sciences in a report on Friday. Cantor Fitzgerald raised their target price on shares of Gilead Sciences from $155.00 to $175.00 and gave the company an "overweight" rating in a research report on Friday. Wells Fargo & Company raised their target price on shares of Gilead Sciences from $165.00 to $190.00 and gave the company an "overweight" rating in a research report on Friday. Finally, Citigroup lifted their price target on shares of Gilead Sciences from $165.00 to $188.00 and gave the company a "buy" rating in a research note on Friday. Twenty-three equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $169.74.
Get Our Latest Analysis on Gilead Sciences
Gilead Sciences News Summary
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: Gilead said it will present late-breaking clinical data and real-world evidence from more than 50 studies at HIV Glasgow 2026 on November 8–11. Updates on HIV therapies, its development pipeline and strategic collaborations could provide catalysts if the results reinforce the company’s leadership in HIV treatment. Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow
- Positive Sentiment: Analysts have raised several Gilead price targets, including targets of $175, $181, $183, $188, $190 and $200. Separately, an updated fair-value estimate rose from $158.65 to $165.31, reflecting improved views of third-quarter execution, the HIV business and pipeline assets. Gilead Sciences Price Target Raised to $200.00 Gilead Stock Fair Value Edges Higher After Analyst Target Increases
- Positive Sentiment: Gilead continues to receive favorable analyst attention, including a Morgan Stanley Buy rating and inclusion among healthcare stocks described as having Strong Buy ratings and high quantitative scores. Gilead Sciences Receives a Buy from Morgan Stanley
- Neutral Sentiment: Former Gilead U.S. Medical Affairs head Dean Hakanson joined GOA Therapeutics as chief medical officer. The move highlights executive experience gained at Gilead, but it does not directly change Gilead’s operations or financial outlook. Former Gilead Head of U.S. Medical Affairs Joins GOA Therapeutics
- Negative Sentiment: One recent earnings analysis characterized Gilead’s outlook as mixed: revenue guidance was raised, but the EPS outlook worsened. That contrast could limit upside by raising concerns about profitability even as the HIV business remains strong. Gilead Sciences Q3 2026 Earnings Analysis
About Gilead Sciences
(
Get Free Report)
Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.
Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
